Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Artificial intelligence in European medicines regulation

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 81-82 (2023)



The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties.

Updates & Corrections

  • Correction 23 November 2022: The section about regulatory access to algorithms and datasets has been modified to remove the statement that the definition of commercially confidential information in the context of AI should mirror the one applicable to clinical trial data. One author, Peter Arlett, was not displaying owing to a platform error that has now been corrected.

Supplementary Information

  1. Supplementary Table 1

Competing Interests

The authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links